RA CAPITAL MANAGEMENT, L.P. — 13F Portfolio

RA Capital Management, L.P. is a Boston-based investment firm specializing exclusively in the life sciences sector, recognized as one of the most influential crossover investors bridging private venture investments and public equity markets in biotechnology and pharmaceuticals. Co-founded by Peter Kolchinsky, PhD, and Rajeev Shah, the firm has established itself as a leading voice in healthcare investing and healthcare policy, combining rigorous scientific analysis with long-term investment horizons. RA Capital files quarterly 13F reports with the Securities and Exchange Commission under CIK #0001346824, providing transparency into its substantial public equity holdings across the life sciences ecosystem. Headquartered in Boston's biotech hub, RA Capital serves an institutional client base including endowments, foundations, pension funds, and family offices seeking specialized exposure to therapeutic innovation and drug development. Peter Kolchinsky, who serves as Managing Partner and Chief Investment Officer, holds a PhD in virology from Harvard University, exemplifying the firm's scientific-first approach to investment analysis. His thought leadership on drug pricing, healthcare economics, and the biotechnology social contract has elevated the firm's profile beyond pure investment management into healthcare policy discourse. The firm's "crossover" investment model represents a distinctive strategy: RA Capital invests in private biotechnology companies during early development stages, then maintains and often increases positions as these companies transition to public markets through IPOs. This private-to-public continuum provides portfolio companies with patient, knowledgeable capital while offering the firm advantaged insight into scientific progress and corporate development. The platform's 13F History tools enable examination of the public equity component of this strategy, revealing how positions evolve from IPO through clinical development milestones.

RA Capital employs a life sciences-focused investment strategy characterized by deep scientific analysis, long-term investment horizons, and crossover positioning spanning private and public markets. The firm's approach rejects short-term trading in favor of partnership-oriented investing, typically maintaining positions through multiple years of clinical development rather than trading around individual catalysts. This patient capital model aligns investor and company interests while enabling meaningful position sizes in promising therapeutic platforms. The 13F Portfolio Composition reveals concentrated positioning across the biotechnology and pharmaceutical landscape, with holdings spanning gene therapy, oncology, rare disease, neurology, and other therapeutic areas where scientific innovation may address significant unmet medical needs. The portfolio reflects the firm's crossover heritage, frequently featuring companies that RA Capital backed in private rounds and continued supporting through public market transitions. The firm's investment process centers on scientific assessment of therapeutic platforms—evaluating biological mechanisms, clinical trial design, competitive positioning, and probability of technical and regulatory success. This analysis draws on the firm's team of scientists and physicians, applying academic-caliber rigor to investment decision-making. The Sector Allocation History across reporting periods demonstrates how positioning evolves across therapeutic subsectors as clinical programs advance, fail, or achieve commercial milestones. Portfolio turnover tends toward the moderate range, reflecting long holding periods for successful investments balanced against position adjustments when clinical or scientific thesis elements change. The firm's conviction-weighted approach results in meaningful position sizes in highest-confidence ideas while maintaining portfolio diversification across the life sciences opportunity set. RA Capital's public commentary and Peter Kolchinsky's writings on drug pricing and the biotechnology social contract reflect an investment philosophy extending beyond pure financial analysis to consider the sustainable economics of therapeutic innovation.

RA Capital Management, L.P. represents a premier life sciences investment firm distinguished by scientific depth, crossover positioning spanning private and public markets, and thought leadership in healthcare investing and policy. The firm's 13F filings under CIK #0001346824 reveal the public equity component of its investment activities, enabling systematic analysis of position evolution, therapeutic subsector allocation, and conviction patterns as portfolio companies progress through clinical development. Key observable characteristics include exclusive life sciences focus, long-term partnership-oriented investment horizons, and concentrated positioning reflecting scientific conviction in therapeutic platforms. The Sharpe Ratio and Annualized Return (CAGR) derived from historical portfolio replication enable quantitative assessment of risk-adjusted performance, while Top 10 Holdings Concentration analysis reveals the degree to which portfolio outcomes depend on highest-conviction positions. The firm's crossover model, scientific expertise, and influential role in biotechnology capital formation distinguish it from both generalist hedge funds and traditional healthcare mutual funds. Peter Kolchinsky's public engagement on drug pricing and biotechnology economics provides additional context for understanding the firm's long-term orientation and stakeholder considerations. For analysts examining the disclosed holdings, a critical question emerges: how does the firm's patient capital approach and crossover positioning perform during extended periods of biotechnology sector underperformance, and what patterns emerge in position sizing or new position initiation as market conditions for life sciences IPOs and capital formation fluctuate?

The risk characteristics of RA Capital's disclosed holdings reflect the inherent volatility and binary outcomes associated with concentrated biotechnology investing. The Volatility Profile of disclosed positions typically exceeds broad market measures significantly, as individual clinical trial results, FDA decisions, and competitive developments can generate substantial single-day price movements independent of general market direction. Drawdown behavior in life sciences-focused portfolios carries distinctive dynamics: biotech sector corrections, clinical trial failures, and regulatory setbacks can generate significant peak-to-trough declines, while successful drug approvals and positive clinical data can produce equally dramatic upside. The Max Drawdown Depth metric available through historical portfolio simulation captures these experiences across various market environments, including the challenging 2021-2023 period for biotechnology valuations. The firm's long-term investment horizon and crossover positioning influence risk characteristics in nuanced ways. Positions acquired during private rounds at lower valuations may provide cushion against public market volatility, while the willingness to maintain positions through clinical development reduces whipsaw risk associated with short-term catalyst trading. However, the concentrated sector focus eliminates diversification benefits available to multi-sector managers. The Downside Capture Ratio derived from historical replication offers perspective on how disclosed holdings have performed during declining markets, though biotechnology often exhibits idiosyncratic behavior relative to broad equity indices—sector-specific factors may dominate general market influences. Platform risk represents another consideration: if a major therapeutic platform underlying multiple portfolio companies encounters scientific challenges, correlated positions may experience simultaneous pressure.